Broadly reactive mosaic peptide for influenza vaccine

US20140286981A1Inactive Publication Date: 2014-09-25WISCONSIN ALUMNI RES FOUND
6 Cites 15 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Broadly reactive mosaic peptide for influenza vaccine
  • Broadly reactive mosaic peptide for influenza vaccine
  • Broadly reactive mosaic peptide for influenza vaccine

Examples

Experimental program
Comparison scheme
Effect test

example i

Materials and Methods

Cells and Viruses

[0108]Chicken embryo fibroblasts (CEFs) and Mardin-Darby canine kidney (MDCK) cells were obtained from Charles River Laboratories, Inc. (Wilmington, Wash.) and the American Type Culture Collection (ATCC, Manassas, Va.), respectively. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. CEFs were used for propagating MVA virus. Highly pathogenic avian influenza (H5N1) virus A / Vietnam / 1203 / 04 was kindly provided by Dr. Yoshihiro Kawaoka (University of Wisconsin-Madison, Wis., USA). Highly pathogenic avian influenza (H5N1) viruses, A / Hongkong / 483 / 97, A / Mongolia / Whooper swan / 244 / 05 and A / Egypt / 1 / 08 and seasonal influenza viruses including A / Puerto Rico / 8 / 34 (PR8, H1N1) and A / Aichi / 2 / 1968 (H3N2) were kindly provided by Dr. Stacey Schultz-Chemy and Dr. Ghazi Kayali (St. Jude children's research hospital, Memphis, Term.). All viruses were propagated and titrated in MDCK cells w...

example ii

[0134]Samples were collected for a microneutralization test at 4 weeks post-immunization. FIG. 7 shows the antibody titers for three different strains of influenza virus in mice immunized with H5M / MVA, inactivated vikeus (Baxter) or MVA alone. The antisera in immunized mice were reactive against three distinct viral clades (HPAI Clade 0, Clade 1, and Clade 2 viruses) after a single dose. The presence of neutralizing antibodies at 4 weeks indicates that the H5M vaccine provides rapid immunity and the immunity is higher than inactivated against the homologous virus. Even recent consensus approaches that have tried to control for the most diversity of input sequence have failed to simultaneously elicit immune responses against all of these clades.

TABLE 1GrpConstructsRouteN =Challenge stains1MVA-H5MID8HK / 483 / 972Inactivated H5N1SC8HK / 483 / 973MVA / LUC - controlID5HK / 483 / 974MVA-H5MID8MONG / 244 / 055Inactivated H5N1SC8MONG / 244 / 056MVA / LUC - controlID5MONG / 244 / 057MVA-H5MID8VN / 1203 / 048Inactivated H...

example 111

[0136]The genetic algorithm was used to generate other mosaic sequences. 4,809 H1 sequences were used to generate 4 H1M sequences, e.g., using default parameters or modified parameters such as a different random seed number. A characteristic residue in one set of those sequences (SEQ ID Nos. 2 and 3) may be at position 125 (Ile), and a characteristic residue in the other set (SEQ ID Nos. 4 and 5) may be at one or more of positions 62 (Lys), 64 (Ile), 68 (Gln), 71 (Asn), 73 (Ser), 74 (Val), 86 (Leu), 88-91 (IleSerLysGlu), 99-103 (LysProAsnProGlu), 111 (His), or 113 (Ala), or corresponding positions (depending on the length of the signal peptide).

[0137]2,931 H3 sequences were used to generate a H3M sequence (SEQ ID NO:7).

[0138]393 H2 sequences were used to generate a H2M sequence (SEQ ID NO:6). A characteristic residue in H2M may be at one or more of positions 24 (Ala), 45 (Lys), 86 (Ser), 258 (Thr), 260 (Asn), or 261 (Leu), or corresponding positions.

[0139]799 H7 sequences were used ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Pharmaceutically acceptableaaaaaaaaaa
Login to View More

Abstract

The invention provides for mosaic influenza virus HA and NA sequences and uses thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of the filing date of U.S. application Ser. No. 61 / 785,071, field on Mar. 14, 2013, the disclosure of which is incorporated by reference herein.STATEMENT OF GOVERNMENT RIGHTS[0002]This invention was made with government support under 2008-55620-19132 awarded by the USDA / NIFA. The government has certain rights in the invention.BACKGROUND[0003]Influenza viruses are a significant health concern for animals and humans. The World Health Organization (WHO) estimates that every year influenza virus infects up to 1 billion people, with 3-5 million cases of severe disease and 300,000-500,000 deaths annually (Meltzer et al., 1999). The traditional approach to controlling influenza A virus is based on diagnosis, treatment and prevention through vaccination. Each of these approaches, however, has flaws (e.g., antiviral resistance, incomplete protection, and improper vaccine distribution), e.g., treating every case ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
25 Sep 2014
Publication
US20140286981A1
IPC
A61K39/145; A61K45/06
CPC
A61K39/145; A61K45/06; C12N2760/16034; C12N7/00; A61K2039/525; C07K14/005; C12N2710/24143; C12N2760/16122
Inventors
OSORIO, JORGE E.; GOLDBERG, TONY